Emmes

Emmes Company, LLC is a contract research organization based in Rockville, Maryland, with an additional office in Frederick, Maryland. Founded in 1977, Emmes specializes in providing comprehensive clinical research services aimed at advancing public health and biopharmaceutical innovation. The organization offers a range of platforms and services, including EMMES AdvantageEDC for electronic data collection, EMMES RTS for regulatory documentation management, and EMMES GlobalTrace for real-time tracking of materials and specimens. Emmes collaborates with leading researchers to address critical health challenges across various areas, such as transplantation, oncology, maternal and child health, and infectious diseases. The company's expertise encompasses statistical leadership, project management, study design, data analysis, quality assurance, and regulatory affairs, ensuring efficient execution of clinical trials and related activities.

Matt Honan

Vice President and Global Head of Corporate Development

Peter Ronco

CEO

7 past transactions

VaxTrials

Acquisition in 2023
VaxTrials is a clinical research organization focused on managing and monitoring vaccination clinical trials. The company offers a variety of services, including project feasibility assessment, site management, clinical supplies management, pharmacovigilance, and safety and medical monitoring. By providing these comprehensive solutions, VaxTrials aims to facilitate the efficient conduct of vaccine trials, ultimately contributing to the eradication of preventable diseases.

Essex Management

Acquisition in 2023
Essex Management specializes in biomedical informatics and health information technology services. The firm offers a range of consulting services tailored to federal government agencies, research institutions, and private sector clients. Their expertise encompasses computational biology, bioinformatics, systems design and engineering, and comprehensive program and project management. By focusing on data management, genetic sequencing, and the development of analytics and algorithms, Essex Management aims to enhance clients' investments in technology and informatics. Additionally, the company provides services such as application engineering, machine learning, integrated process automation, and stakeholder management, all designed to improve outcomes for patients and clinicians.

Clinical Edge

Acquisition in 2022
Clinical Edge offers Visual Acuity Examiner and Visual Acuity Room Certification to ensure quality and consistency amongst clinical sites participating in the conduct of Ophthalmology drug, biologic, and device trials.

Casimir

Acquisition in 2022
Casimir is a contract research organization that emphasizes the patient's perspective in its clinical studies, particularly in the context of rare diseases. The company utilizes innovative approaches, such as virtual trials and remote assessments, to enhance understanding of disease progression and treatment effects. By focusing on qualitative research, Casimir aims to capture the real-world impact of treatment interventions on patient quality of life through intelligent outcome measures. This commitment to prioritizing the patient experience allows Casimir to contribute valuable insights into the effectiveness of medical treatments.

Institut Dr. Schauerte

Acquisition in 2021
Institut Dr. Schauerte (IDS) is a clinical research organization based in Munich that provides a range of services focused on late-phase, non-interventional studies, including post-market clinical follow-up (PMCF) and registry studies. The organization is dedicated to complex study designs tailored to meet the unique requirements of investigator-initiated trials (IITs) and emphasizes the importance of real-world evidence in the healthcare and biopharmaceutical sectors. By offering secure and user-friendly e-clinical solutions, IDS supports study centers in advancing public health and fostering innovation within the pharmaceutical industry.

Orphan Reach

Acquisition in 2021
Orphan Reach is a global and full-service CRO that has built a reputation for outstanding clinical research addressing rare diseases. We offer global clinical development services that allow our clients to take their precious IMP from early trials in patients to Marketing Authorization. From Project Management to Clinical Monitoring, Safety & Pharmacovigilance, Quality Assurance, Data Management, and Biostatistics: we provide a seamless CRO service. What makes us stand out is the refinement of our processes and adaptation of services to accommodate clinical trials involving small patient numbers. Dealing efficiently with the unique medical, scientific, clinical, and commercial challenges within the rare disease domain, is what our clients appreciate.

Neox CRO

Acquisition in 2020
Neox is a privately owned full services clinical CRO. We conduct clinical trials for pharmaceutical, biotechnology, medical device companies and other CRO’s throughout Europe and US. Our services are offered for Phase I-IV. DRUG DEVELOPMENT - Medical Writing, Site Contracting, Clinical Monitoring, Project Management, Pharmacovigilance, Regulatory, Medical Monitoring, Outsourcing. MEDICAL DEVICE DEVELOPMENT PHARMACOVIGILANCE & REGULATORY REAL WORLD EVIDENCE/DATA & HEOR DATA MANAGEMENT & BIOSTATISTICS We offer our services as a full service package or individually as a tailored solution to your specific needs. Where We Are: Years of clinical research experience, understanding local requirements and established relationships with investigators ensures that your trial will always be performed in an optimal setting for high patient enrollment. Neox offices: Czechia, California, Germany, Poland, Hungary, Bulgaria, Slovakia, Romania. Neox also operates in: Austria, Belgium, Estonia, France, Finland, Italy, Latvia, Lithuania, Netherlands, Spain, United Kingdom and others.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.